CD274 and non-small cell lung carcinoma: The IMpower010 phase III clinical trial (NCT02486718) showed that atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA NSCLC could improve disease-free survival, especially in patients whose tumors had increased PD-L1 expression [55].